Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 May 2014

Corless Christopher L, Ballman Karla V, Antonescu Cristina R, Kolesnikova Violetta, Maki Robert G, Pisters Peter W T, Blackstein Martin E, Blanke Charles D, Demetri George D, Heinrich Michael C, von Mehren Margaret, Patel Shreyaskumar, McCarter Martin D, Owzar Kouros, DeMatteo Ronald P

Abstract excerpt

PURPOSE: The ACOSOG (American College of Surgeons Oncology Group) Z9001 (Alliance) study, a randomized, placebo-controlled trial, demonstrated that 1 year of adjuvant imatinib prolonged recurrence-free survival (RFS) after resection of primary GI stromal tumor (GIST). We sought to determine the pathologic and molecular factors associated with patient outcome. PATIENTS AND METHODS: There were 328 patients assigned...

Topics

Join the communities discussing this publication.

Benzamides
Chemotherapy, Adjuvant
Gastrointestinal Stromal Tumors
Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Patient Selection

Receptor, Platelet-Derived Growth Factor alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 24638003
DOI: 10.1200/JCO.2013.51.2046
PMCID: PMC4026579

Genes

KIT
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.PMID 24638003Read ↗

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.Semantic proximity Read ↗

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial.Semantic proximity Read ↗

Prognostic Stratification of High-risk Gastrointestinal Stromal Tumors in the Era of Targeted TherapySemantic proximity Read ↗

Molecular Features of Gastrointestinal Stromal Tumors: A Single Referral Cancer Center Experience.Semantic proximity Read ↗

Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.Semantic proximity Read ↗

Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.Semantic proximity Read ↗

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).Semantic proximity Read ↗

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.Semantic proximity Read ↗

Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.Semantic proximity Read ↗

Impact of Mutation Profile on Outcomes of Neoadjuvant Therapy in GISTSemantic proximity Read ↗

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.Semantic proximity Read ↗

Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.